FDA determined on December 19, 2024 that the tirzepatide injection shortage was resolved, and on February 21, 2025 that the semaglutide injection shortage was resolved
Screw the needle onto the pen until its secure, but be careful not to overtighten
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
for many, it feels less medicalized than giving oneself a shot
Clinical studies have shown that patients can lose a significant percentage of their body weight over several months when using Semaglutide alongside lifestyle adjustments
